Syncope and seizures following human papillomavirus vaccination: a retrospective case series

Syncope and seizures following human papillomavirus vaccination: a retrospective case series
复制标题

DOI:
10.5694/j.1326-5377.2011.tb04138.x
复制
发表时间:
2011-01-03
影响因子:
11.4
通讯作者:
Buttery, Jim P.
Buttery, Jim P.
中科院分区:
医学2区
文献类型:
--
作者:
Crawford, Nigel W.;Clothier, Hazel J.;Buttery, Jim P.

文献摘要

被引文献

相似文献

目的:量化和描述四价 (4v) 人乳头瘤病毒 (HPV) 疫苗接种后晕厥和癫痫发作的报告。设计和设置:向 SAEFVIC(社区疫苗接种后不良事件监测)通知的回顾性病例系列,2007 年 5 月,2009 年 4 月。主要结果指标:。 4vHPV 疫苗接种后晕厥和癫痫发作的发生率;临床结果。结果:97/1653 SAEFVIC 报告符合研究标准:无热惊厥 (3)、晕厥发作 (31) 和单纯晕厥 (63)。接种疫苗的中位年龄为 15 岁(范围为 8-26 岁)。据报告有七起受伤事件,其中包括一例椎骨骨折。对 41% (40/97) 的患者进行了 SAEFVIC 临床审查,其中 22 名患者接受了仰卧位进一步注射的 4vHPV 疫苗剂量,没有复发。接种 4vHPV 疫苗后晕厥和晕厥癫痫发作的报告率分别为 7.8/100 000 剂和 2.6/100 000 剂。结论:维多利亚州接种 4vHPV 疫苗后晕厥和晕厥癫痫发作的发生率与国际水平相似。临床审查可以澄清诊断和管理,包括在监督下安全施用更多剂量。
Objective: To quantify and characterise the reports of syncope and seizures following quadrivalent (4v) human papillomavirus (HPV) vaccination.Design and setting: Retrospective case series of notifications to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), May 2007 April 2009.Main outcome measures:. Incidence of syncope and seizure following 4vHPV vaccination; clinical outcomes.Results: 97/1653 SAEFVIC reports met the study criteria: afebrile seizures (3), syncopal seizures (31) and syncope alone (63). Median age at vaccination was 15 years (range, 8-26 years). Injuries were reported in seven cases, including one vertebral fracture. A SAEFVIC clinic review was undertaken in 41% (40/97) and 22 patients received further 4vHPV vaccine doses administered supine, with no recurrences. The reporting rate after 4vHPV vaccine for syncope and syncopal seizures was 7.8/100 000 and 2.6/100 000 doses distributed, respectively.Conclusion: Syncope and syncopal seizures occurred after 4vHPV vaccination in Victoria at rates similar to those seen internationally. Clinical review allowed clarification of the diagnosis and management, including safe administration of further doses under supervision.